The DOJ asked the U.S. Supreme Court on Friday for an emergency stay on an appeals court ruling that was set to limit access to an abortion pill known as mifepristone, ABC News reported.
This comes after the Fifth Circuit Court of Appeals granted an emergency stay requested by the DOJ on a Texas judge’s decision to halt the FDA’s approval of the abortion drug, per LifeSiteNews.
Mifepristone is not a new drug. The FDA approved a generic version of the abortifacient (which is usually used with misoprostol) in 2019, formulating 200 mg tablets for prescription use. However, the use of the drug dates back to 2000.
The suspension of the FDA’s approval of the drug was made in early April in the Lone Star State by Texas Judge Matthew Kacsmaryk. LifeSiteNews previously reported that the ruling would have applied to all 50 states on April 14, halting the distribution of mifepristone.
ABC revealed that the DOJ argued this was “the first time any court has abrogated FDA’s conditions on a drug’s approval based on a disagreement with the agency’s judgment about safety — much less done so after those conditions have been in effect for years.”
Judge Kacsmaryk’s ruling comes less than a year after the U.S. Supreme Court ruled to overturn Roe v. Wade (1973) and its subsequent reaffirmation ruling, Planned Parenthood v. Casey (1992).
“Today’s decision, which is the biggest WIN for LIFE in a generation, along with other decisions that have been announced recently, were only made possible because I delivered everything as promised, including nominating and getting three highly respected and strong Constitutionalists confirmed to the United States Supreme Court,” President Donald Trump stated in 2022, shortly after Roe v. Wade was overturned.
LifeSiteNews reported that Judge Kacsmarky was appointed by President Trump.